Stocks Health care CATX
NYSE · Health carePerspective Therapeutics, Inc. (CATX)
It posted a net loss of $122.9M. In fiscal 2025 capital spending exceeded operating cash flow by $95.2M. At September 30, 2026 it held $41M in cash against $1.6M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about Perspective Therapeutics, Inc.
- Net worth
- Perspective Therapeutics, Inc. has a market value (market cap) of $97.7M at the latest share price, and shareholders' equity of $294.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2023 revenue was $1.4M, with a net loss of $46.5M.
- Cash flow
- In fiscal 2025 operations used $82.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Perspective Therapeutics, Inc.'s next report is expected around January 8, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Perspective Therapeutics, Inc. does
Perspective Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker CATX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$103.1M | -$1.40 | -$95.2M |
| 2024 | n/a | -$79.3M | -$1.23 | -$72.7M |
| 2023 | $1.4M | -$46.5M | -$1.74 | -$38M |
| 2023 | $0 | -$10.8M | -$0.82 | -$10.7M |
| 2022 | $10.8M | -$7.3M | -$0.51 | -$8M |
| 2021 | $10.1M | -$3.4M | -$0.31 | -$3.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Perspective Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- November 9, 2026
- November 6, 2026Other event 8-K
- November 6, 2026Other event 8-K
- October 23, 2026Other event 8-K
- October 8, 2026Other event 8-K
- October 1, 2026Other event 8-K
- September 14, 2026Other event 8-K
- September 8, 2026Other event 8-K
- August 13, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Perspective Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $357.2K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 1, 2026 | Lantheus Alpha Therapy, LLC10% owner | Sold | 35,769 | $111.6K |
| August 31, 2026 | Lantheus Alpha Therapy, LLC10% owner | Sold | 78,145 | $245.6K |
| November 13, 2025 | Hunt Jonathan RobertChief Accounting Officer | Bought | 11,000 | $22.3K |
| November 12, 2025 | Williamson Robert F IIIDirector | Boughtindirect | 9,498 | $19.9K |
Who owns CATX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Commodore Capital LP13G, passive with 3 related filers | 9.9% | February 9, 2026 |
| Chen Yu13G, passive with 4 related filers | 6.9% | February 6, 2026 |
| Qatar Investment Authority13G, passive | 6.2% | February 5, 2026 |
| Millennium Management LLC13G, passive with 3 related filers | 5.5% | August 13, 2026 |
| Avidity Partners Management LP13G, passive with 5 related filers | 5.3% | March 10, 2026 |
Largest institutional holders
Insiders
3 insiders reported holding 11,633,089 shares in total, about $10M at the last price.
| Holder | Shares |
|---|---|
| Lantheus Alpha Therapy, LLC10% owner | 11,563,425 |
| Hunt Jonathan RobertChief Accounting Officer | 59,800 |
| Williamson Robert F IIIDirector | 9,8649,864 held indirectly |
Questions about CATX
What does Perspective Therapeutics, Inc. do?
Perspective Therapeutics, Inc. is a company in the Health care sector, listed on NYSE as CATX. Its shares trade on NYSE under the ticker CATX.
What is Perspective Therapeutics, Inc.'s net worth?
Perspective Therapeutics, Inc. has a market value (market cap) of $97.7M at the latest share price, and shareholders' equity of $294.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Perspective Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $122.9M.
When did Perspective Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is Perspective Therapeutics, Inc.'s next earnings report?
Perspective Therapeutics, Inc.'s next report is expected around January 8, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare CATX with
Follow CATX
Get an email when Perspective Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Perspective Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.